IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.

Broto, Javier Martín; Hindi, Nadia; Redondo, Andrés; Martínez‐Trufero, Javier; Stacchiotti, Silvia; Palmerini, Emanuela; Álava, Enrique de; Moura, David Silva; Vega, Herminia Pérez; Otero, Irene; Ledesma, Patricio; Marchesi, Emanuela; López-Martín, José A.

doi:10.1200/jco.2018.36.15_suppl.11515

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, no data are available on the efficacy of gemcitabine. Besides cytotoxics, antiangiogenic agents represent a promising alternative systemic treatment, with an antitumor effect that is superior to that seen in the majority of other STSs [ 39 , 40 , 42 , 60 , 61 , 62 ].…”

Section: State Of the Art: Advanced Diseasementioning

confidence: 99%

“…EMC displays an interesting immune infiltration pattern [ 40 ], however, only very preliminary data are currently available on the activity of programmed cell-death protein 1/programmed death-ligand 1 (PD1/PDL1) inhibitors in EMC [ 68 ]. The Spanish and the Italian Sarcoma Group recently conducted a phase I–II single-arm trial (NCT03277924) with the combination of sunitinib and nivolumab in several histotypes of soft tissue and bone sarcomas observing, among others, one RECIST and two Choi partial responses out of four patients with EMC enrolled in the trial [ 62 ]. However, the study design does not allow for understanding what has been contributed in terms of antitumor effect by the addition of nivolumab to sunitinib.…”

Section: Current Research and Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management

Stacchiotti

Baldi

Morosi

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare mesenchymal neoplasm with uncertain differentiation, which arises mostly in the deep soft tissue of proximal extremities and limb girdles. EMC is marked by a translocation involving the NR4A3 gene, which can be fused in-frame with different partners, most often EWSR1 or TAF1. Although EMC biology is still poorly defined, recent studies have started shedding light on the specific contribution of NR4A3 chimeric proteins to EMC pathogenesis and clinical outcome. Standard treatment for localized disease is surgery, plus or minus radiation therapy with an expected prolonged survival even though the risk of relapse is about 50%. In advanced cases, besides the standard chemotherapy currently used for soft tissue sarcoma, antiangiogenic agents have recently shown promising activity. The aim of this review is to provide the state of the art of treatment for localized and advanced disease, with a focus on pharmacological treatments available for EMC. The biological basis of current research and future perspectives will be also discussed.

show abstract

Section: State Of the Art: Advanced Diseasementioning

confidence: 99%

Section: Current Research and Future Perspectivesmentioning

confidence: 99%

Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management

Stacchiotti

Baldi

Morosi

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma

et al. 2020

View full text Add to dashboard Cite

Background Sarcomas represent 10%–15% of cancers in adolescent and young adult (AYA) patients, and survival for those with metastatic disease or relapse is poor. Immunotherapy with checkpoint inhibition has improved outcomes in multiple tumor types, but data in advanced sarcomas, particularly within the AYA population, are limited. Aim We aim to evaluate response and toxicity for AYA patients with sarcoma treated with pembrolizumab. Methods and results We retrospectively reviewed AYA patients with advanced bone and soft tissue sarcoma who received self‐funded pembrolizumab between May 2015 and January 2019. Eighteen patients were identified. One patient with Ewing sarcoma had a sustained complete response to therapy. Two patients with alveolar soft part sarcoma received a clinical benefit from pembrolizumab: one had a radiological partial response with an excellent clinical response and one patient achieved stable disease. Four patients died of disease prior to first scheduled assessment and thus were not evaluable. The remaining eleven patients had progressive disease. Conclusion The role of immunotherapy in AYA sarcoma warrants further investigation. Biomarkers of response need to be further evaluated in order to guide patient selection.

show abstract

Role of TKI for Metastatic Osteogenic Sarcoma

Duffaud

2020

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.

Cited by 8 publications

References 0 publications

Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management

Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management

PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma

Role of TKI for Metastatic Osteogenic Sarcoma

Contact Info

Product

Resources

About